Insmed, Inc. (INSM) Scheduled to Post Earnings on Thursday
Insmed, Inc. (NASDAQ:INSM) is scheduled to be releasing its earnings data before the market opens on Thursday, November 2nd. Analysts expect Insmed to post earnings of ($0.69) per share for the quarter.
Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.09). On average, analysts expect Insmed to post $-2.70 EPS for the current fiscal year and $-2.28 EPS for the next fiscal year.
Insmed, Inc. (NASDAQ INSM) opened at 26.43 on Thursday. The firm has a 50-day moving average price of $29.04 and a 200-day moving average price of $19.50. Insmed, Inc. has a 1-year low of $10.21 and a 1-year high of $31.84. The firm’s market capitalization is $1.65 billion.
TRADEMARK VIOLATION WARNING: “Insmed, Inc. (INSM) Scheduled to Post Earnings on Thursday” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/10/26/insmed-inc-insm-scheduled-to-post-earnings-on-thursday.html.
A number of analysts have weighed in on INSM shares. Leerink Swann increased their price target on Insmed from $27.00 to $36.00 and gave the stock an “outperform” rating in a report on Tuesday, September 5th. Stifel Nicolaus reiterated a “buy” rating and set a $43.00 price target (up from $27.00) on shares of Insmed in a report on Wednesday, September 6th. Evercore ISI increased their price target on Insmed from $28.00 to $40.00 and gave the stock an “outperform” rating in a report on Tuesday, September 5th. Zacks Investment Research upgraded Insmed from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a report on Wednesday, July 5th. Finally, Robert W. Baird started coverage on Insmed in a report on Monday, July 10th. They set an “outperform” rating and a $23.00 price target for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. Insmed presently has a consensus rating of “Buy” and an average target price of $34.50.
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.